Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 2/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.42 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.40 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.40 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.40 |
| ▸ | NT5E | P21589 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19927403 | 1.00 | AHCY (0.53) | AHCYADORA1ALDH1A1HIF1AP2RY12 | |
| SCHEMBL19145869 | 0.88 | ADORA3 (0.50) | ADORA1ALDH1A1HIF1AP2RY12ADORA3 | |
| SCHEMBL19927246 | 0.85 | PRMT6 (0.45) | AHCYP2RY12 | |
| SCHEMBL19927242 | 0.85 | PRMT6 (0.45) | AHCYP2RY12 | |
| SCHEMBL13986331 | 0.85 | AHCY (0.64) | AHCYADORA1ALDH1A1HIF1AADORA3 | |
| SCHEMBL21565155 | 0.82 | AHCY (0.53) | AHCYADORA1ALDH1A1HIF1AP2RY12 | |
| SCHEMBL19927540 | 0.82 | AHCY (0.53) | AHCYADORA1ALDH1A1HIF1AP2RY12 | |
| SCHEMBL29832246 | 0.81 | ADORA1 (0.49) | ADORA1P2RY12NT5E | |
| SCHEMBL19127764 | 0.81 | ADORA1 (0.49) | ADORA1P2RY12NT5E | |
| SCHEMBL24465182 | 0.77 | ALDH1A1 (0.56) | AHCYADORA1ALDH1A1HIF1AP2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190345191-A1 | CYCLIC DINUCLEOTIDE ANALOGS FOR TREATING CONDITIONS ASSOCIATED WITH STING (STIMULATOR OF INTERFERON GENES) ACTIVITY | INNATE TUMOR IMMUNITY INC (US) | 2019-11-14 | — | — | US | disclosed |
| WO-2018045204-A1 | CYCLIC DINUCLEOTIDE ANALOGS FOR TREATING CONDITIONS ASSOCIATED WITH STING (STIMULATOR OF INTERFERON GENES) ACTIVITY | IFM THERAPEUTICS, INC (US) | 2018-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190345191-A1 | CYCLIC DINUCLEOTIDE ANALOGS FOR TREATING CONDITIONS ASSOCIATED WITH STING (STIMULATOR OF INTERFERON GENES) ACTIVITY | STING1, CGAS, IRF3 | AHCY 1727/4885ADORA1 410/4885ALDH1A1 4646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.